|
ZNF644 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.50529588793802E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.37340028238953E-10 |
| Normal-vs-Stage2 |
1.94549998333571E-09 |
| Normal-vs-Stage3 |
6.16173778666962E-14 |
| Normal-vs-Stage4 |
1.64590563400679E-12 |
| Stage1-vs-Stage2 |
6.279800E-01 |
| Stage1-vs-Stage3 |
1.288560E-01 |
| Stage1-vs-Stage4 |
3.827800E-04 |
| Stage2-vs-Stage3 |
5.753800E-01 |
| Stage2-vs-Stage4 |
1.818100E-02 |
| Stage3-vs-Stage4 |
4.679600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.88882284549663E-12 |
| Normal-vs-AfricanAmerican |
2.48880000000007E-05 |
| Normal-vs-Asian |
2.56869969739171E-10 |
| Caucasian-vs-AfricanAmerican |
6.161600E-01 |
| Caucasian-vs-Asian |
7.971800E-01 |
| AfricanAmerican-vs-Asian |
7.399400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.65440019858931E-10 |
| Normal-vs-Female |
8.42359515473845E-12 |
| Male-vs-Female |
1.750160E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.73679967577323E-10 |
| Normal-vs-Age(41-60Yrs) |
3.01481062336961E-12 |
| Normal-vs-Age(61-80Yrs) |
2.06139549874251E-11 |
| Normal-vs-Age(81-100Yrs) |
4.603400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.324400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.672230E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.831800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.532800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.793800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.324800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.865910E-02 |
| Classical-VS-Follicular |
1.356200E-01 |
| Classical-VS-Other |
7.005000E-01 |
| Classical-VS-Normal |
1.51709977913583E-10 |
| Tall-VS-Follicular |
6.203300E-03 |
| Tall-VS-Other |
1.252410E-01 |
| Tall-VS-Normal |
9.96058791002952E-12 |
| Follicular-VS-Other |
9.123000E-01 |
| Follicular-VS-Normal |
3.750100008304E-09 |
| Other-VS-Normal |
1.075960E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50049988995238E-11 |
| Normal-vs-N1 |
2.21680451772954E-11 |
| N0-vs-N1 |
3.093400E-01 |
|
|
